These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25688562)

  • 1. Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.
    Hsieh YT; Chen KC; Cheng CM; Cheng TL; Tao MH; Roffler SR
    PLoS One; 2015; 10(2):e0118028. PubMed ID: 25688562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
    Huang PT; Chen KC; Prijovich ZM; Cheng TL; Leu YL; Roffler SR
    Cancer Gene Ther; 2011 Jun; 18(6):381-9. PubMed ID: 21350582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours.
    Tobin PJ; Dodds HM; Clarke S; Schnitzler M; Rivory LP
    Oncol Rep; 2003; 10(6):1977-9. PubMed ID: 14534729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model.
    Dodds HM; Tobin PJ; Stewart CF; Cheshire P; Hanna S; Houghton P; Rivory LP
    J Pharmacol Exp Ther; 2002 Nov; 303(2):649-55. PubMed ID: 12388647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
    Cheng KW; Tseng CH; Tzeng CC; Leu YL; Cheng TC; Wang JY; Chang JM; Lu YC; Cheng CM; Chen IJ; Cheng YA; Chen YL; Cheng TL
    Pharmacol Res; 2019 Jan; 139():41-49. PubMed ID: 30391354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs.
    Tseng YH; Lin HP; Lin SY; Chen BM; Vo TNN; Yang SH; Lin YC; Prijovic Z; Czosseck A; Leu YL; Roffler SR
    J Control Release; 2024 May; 369():179-198. PubMed ID: 38368947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted bacteria-mediated therapy of mouse colorectal cancer using baicalin, a natural glucuronide compound, and E. coli overexpressing β-glucuronidase.
    Jafari B; Bahrami AR; Matin MM
    Int J Pharm; 2023 Jul; 642():123099. PubMed ID: 37271252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
    Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
    Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored beta-glucuronidase.
    Su YC; Chuang KH; Wang YM; Cheng CM; Lin SR; Wang JY; Hwang JJ; Chen BM; Chen KC; Roffler S; Cheng TL
    Gene Ther; 2007 Apr; 14(7):565-74. PubMed ID: 17235292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.
    Cheng CM; Chen FM; Lu YL; Tzou SC; Wang JY; Kao CH; Liao KW; Cheng TC; Chuang CH; Chen BM; Roffler S; Cheng TL
    Cancer Gene Ther; 2013 May; 20(5):276-81. PubMed ID: 23598434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
    Narita M; Nagai E; Hagiwara H; Aburada M; Yokoi T; Kamataki T
    Xenobiotica; 1993 Jan; 23(1):5-10. PubMed ID: 8484262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats.
    Yamamoto M; Kurita A; Asahara T; Takakura A; Katono K; Iwasaki M; Ryuge S; Wada M; Onoda S; Yanaihara T; Yokoba M; Mitsufuji H; Nishii Y; Fukui T; Masuda N
    Oncol Rep; 2008 Oct; 20(4):727-30. PubMed ID: 18813810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
    Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
    Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
    Mallick P; Shah P; Gandhi A; Ghose R
    Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
    Kehrer DF; Yamamoto W; Verweij J; de Jonge MJ; de Bruijn P; Sparreboom A
    Clin Cancer Res; 2000 Sep; 6(9):3451-8. PubMed ID: 10999728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
    Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
    Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
    Chen KC; Schmuck K; Tietze LF; Roffler SR
    Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.